New York, U.S. | Xinhua | U.S. pharmaceutical giant Johnson & Johnson on Tuesday trimmed its forecasts on sales and adjusted earnings per share (EPS) in 2022 due to appreciation of the U.S. dollar, and suspended COVID-19 vaccine sales guidance due to a global supply surplus and demand uncertainty. Johnson & …
Read More »